Skip to content

Percutaneous Electric Neurostimulation of Dermatome T7 Improves Glycemic Profile in Obese and Typo 2 Diabetic Patients

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02122874
Enrollment
60
Registered
2014-04-25
Start date
2013-01-31
Completion date
2014-04-30
Last updated
2014-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Type 2 in Obese, Type 2 Diabetes Mellitus With Features of Insulin Resistance

Keywords

Percutaneous neurostimulation; dermatome T7, type 2 diabetes

Brief summary

Percutaneous neurostimulation of dermatome T7 increases Insulin segregation by the apancreas and improves glycemic profile in diabetic patients

Interventions

DEVICEPercutaneous Neurostimulation (PENS) of dermatome T7

The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet

OTHER1200 Kcal diet

Sponsors

Hospital General Universitario Elche
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* BMI\>30 Kg/m2 * Type 2 diabetes mellitus * Treatment with Metformin

Exclusion criteria

* Under insulin treatment * Endocrinological disorders causing diabetes mellitus

Design outcomes

Primary

MeasureTime frameDescription
Serum glucose levels (mg/dl)Baseline and 12 weeks after beginning the therapySerum glucose levels will be recorded will be recorded at baseline and 12 weeks after beginning the treatment. Measurement units will be mg/dl.

Secondary

MeasureTime frameDescription
Homeostasis model assessment (HOMA)Baseline and 12 weeks after beginning the therapyInsulin resistance will be recorded by the Homeostasis model assessment (HOMA). The calculation formula is: Serum Glucose x Serum Insulin / 405

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026